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Activation of the COX2-PGE2 axis by immune
effector cells results in the self-limiting nature of
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Type-1 immune responses, mediated by IFNg and TNFa-
producing CTLs, Th1, and NK cells, are essential for effec-
tive anti-tumor immunity. Despite recent advances in the
induction and stabilization of these responses by cancer
immunotherapies, the clinical success of these approaches
remain limited. Here, we report that the activation of
type-1 immunity within the human tumor microenviron-
ment (TME) initiates IFNg- and TNFa-dependent coun-
ter-regulation, driven by amplification of prostaglandin E2
(PGE2) and the key regulator of PGE2 synthesis, cyclooxy-
genase 2 (COX2). We demonstrate that type-1-activated
CTLs and NK cells induce IFNg/TNFa-mediated over-
expression of indoleamine 2,3-dioxygenase (IDO), induci-
ble nitric oxide synthase (iNOS/NOS2), IL-10, and COX2
by tumor-associated myeloid-derived suppressor cells
(MDSCs). Importantly, this self-limiting suppressive feed-
back driven by type-1 immunity could be eliminated not
only by neutralization of IFNg and TNFa, the factors
critically required for the anti-tumor activity of immune
effector cells, but also by COX2 blockade, which counter-
acted the IFNg/TNFa-driven enhancement of all other
suppressive factors, amplifying the therapeutic potential of
intratumoral type-1 immunity. Our data demonstrate an
intrinsic mechanism underlying the self-limiting character
of type-1 immunity within the human TME, and provide
rationale for targeting the COX2-PGE2 axis to enhance
desirable type-1 responses for cancer immunotherapy.
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